Informations

Advances in medical oncology for breast cancer are reshaping the approach to drug dosing and regimen design. Traditional chemotherapy development relied heavily on identifying the maximum tolerated dose (MTD)—the highest dose patients could endure without severe side effects. However, the focus in modern drug development, particularly for molecular targeted therapies, is shifting toward individualized dose…

From December 6–8, 2024, the ESMO Asia Annual Meeting was held in Singapore, presenting groundbreaking research in oncology. Among the key highlights was the DESTINY-Gastric06 (DG06) study, which sparked extensive discussion. Oncology Frontier invited Prof. Zhi Peng, a leading researcher and specialist from Peking University Cancer Hospital, to share the latest findings from the DG06…

The 47th San Antonio Breast Cancer Symposium (SABCS), held from December 10–13, 2024, in San Antonio, USA, showcased the latest breakthroughs in breast cancer research, clinical practices, and technological innovations. This edition of “SABCS Broadcast” is hosted by Prof. Yongmei Yin from Jiangsu Provincial People’s Hospital, with live reporting by Prof. Junjie Li from Fudan…

At the 2024 European Society for Medical Oncology Asia Congress (ESMO ASIA 2024), during the Preferred Oral Presentations on Thoracic Oncology, Professor Yilong Wu from Guangdong Provincial People’s Hospital presented the positive results of the PACIFIC-5 Phase III trial (Abstract No: LBA6). This study evaluated the efficacy of durvalumab consolidation therapy in unresectable Stage III…

Liquid biopsy is not a new concept in the field of breast cancer, but its clinical applications continue to evolve, requiring fresh insights into the technologies, terminology, biomarkers, and future directions. On Tuesday, December 10 (Central Time), during the “Educational Session 2: Liquid Biopsy: MRD, ctDNA, and Monitoring Response to Treatment” at the 2024 San…

Pathogenic germline mutations in certain genes are known to increase the risk of hereditary breast cancer. Approximately 5% to 10% of all breast cancer cases are hereditary, primarily driven by such mutations, with BRCA1/2 being the most common. Germline mutations also guide treatment decisions, as patients with pathogenic BRCA1/2 germline mutations may benefit from PARP…

On September 19, 2024, a randomized, double-blind, parallel-controlled, multicenter phase III clinical study, co-led by Professor Shukui Qin from the Nanjing Tianyinshan Hospital Affiliated to China Pharmaceutical University and Professor Liwei Wang from the Renji Hospital, Shanghai Jiaotong University School of Medicine, was published in Signal Transduction and Targeted Therapy (IF = 40.8), a prestigious…

From December 10–13, 2024, the 47th San Antonio Breast Cancer Symposium (SABCS) took place in San Antonio, USA. As one of the largest and most prestigious gatherings in breast cancer research, SABCS showcased cutting-edge developments from the past year, including research breakthroughs, clinical practice insights, treatment advances, and technological innovations. Among these, studies led or…